Kornimate/medical-research-clean huggingface dataset:
a study into the effectivity and safety of firmagon, prescribed for treatment of patients with advanced prostate cancer

Conditions: Prostate Cancer

Summary: patients eligible for hormone ablation therapy who are prescribed firmagon will be followed for a maximum of 3 years to estimate the progression free survival. data on testosteron levels, qol and luts will be collected if this information is available. safety information (adverse events) will be collected.


Eligibility criteria:
inclusion criteria: - patients with advanced hormone-dependent prostate carcinoma that are eligible for hormone therapy exclusion criteria: - patients with a contraindication for prescription of firmagon®
feasibility assessment of the aquadex flexflowtm ultrafiltration system in treating non hospitalized heart failure patients in dedicated heart failure centers

Conditions: Heart Failure

Summary: ultrafiltration (uf) technology is unique for its ability to extract fluid as an isotonic solution, therefore not causing substantial changes in nacl concentrations, and the use of peripheral veins makes it feasible to use in out of hospital medical centers, for non compensated heart failure (hf) with a low response to diuretics. the use of uf in the united states and europe in out of hospital hf centers is accepted as daily practice. therefore the hypothesis of this study is that it is feasible for a professional team to effectively use the uf for short courses on non compensated hf patients with low or no response to diuretics, in a dedicated out of hospital hf center.

the patients will be treated in the lin heart failure center and will not include population defined in the exclusion criteria. up to 60 patients will be recruited and each one will undergo up to 30 treatments in time intervals defined by the cardiologist according to the clinical needs throughout the duration of the study. inclusion duration of every patient will be terminated at the end of the treatment course. no prevention in adding more treatment courses per patient according to clinical needs upon the cardiologist's decision. operating the uf system: during the treatment course two of the patient's peripheral veins will be cannulated. one will be used to draw blood from, and the other will be used to return the blood back in to the patient. the patient will be administered with heparin iv, or clexane sc with an act target of 180-200 that will be monitored every 4-6 hours. fluid removal rate will be according to the cardiologists discretion and will not exceed 500 ml/hour patient monitoring - pulse and bp will be recorded at baseline, after 10 minutes for treatment onset and every 1 hour.

Eligibility criteria:
inclusion criteria: hf patients with peripheral or pulmonic fluid retention, with little or no response to diuretics as defined by the referring cardiologist exclusion criteria: 1. age \< 18 years 2. patient does not fully comprehend the essence of the study and can not sign the informed consent. 3. patient is participating in a drug or any other treatment study (no prevention to include patients participating in studies of non invasive monitoring technologies. 4. presence of acute mi 5. cr base values \> 3mg/dl 6. hemodynamic instability requiring inotropic agents 7. ht base values \> 45% 8. known pregnancy 9. presence of contraindication to anticoagulants 10. post heart transplant or cardiac assist device implantation -

Keywords: feasibility of using the flexflowtm ultrafiltration pump in a non hospital environment
a brief intervention for patients on opioids for acute pain

Conditions: Acute Pain

Summary: this study aims to evaluate benefits of a brief intervention for patients who are prescribed opioids for acute pain.


Eligibility criteria:
inclusion criteria: * patients who are admitted to henry ford hospital * patients who have been evaluated by the psychosomatic medicine service * patients who are prescribed at least one opioid for an acute pain condition exclusion criteria: * patients taking an opioid for a chronic pain condition within the previous year * history of an opioid use disorder.
abx-egf (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body

Conditions: Prostate Cancer

Summary: a clinical trial examining the safety and effectiveness of abx-egf when given to patients with prostate cancer with or without tumor in other parts of the body. patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.


Eligibility criteria:
inclusion criteria: * male 18 years of age or older * has tumor tissue available for diagnostics * failed front line luteinizing hormone-releasing hormone analogue (lhrh) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. patients must continue on a lhrh analogue (unless the patient had an orchiectomy) throughout the course of the study * ecog score of 0 or 1 exclusion criteria: * any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior egfr targeting agent) * prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed) * known to be hiv positive * myocardial infarction within one year prior to entering the study

Keywords: prostate cancer psa hormone refractory rising psa
viral excretion among covid-19 omicron recurrence patients

Conditions: COVID-19 Recurrence; Surface Contamination

Summary: the study analyzes the viral nucleic acid excretion and its influencing factors of sars-cov-2 omicron recurrence patients.


Eligibility criteria:
inclusion criteria: * patients with nucleic acid detection n gene and orf gene ct value \< 40 after discharge from hospital * being able to provide basic information, living habits, vaccination information, admission information exclusion criteria: * single gene target positive * patients with incomplete baseline data
stand: ischemic stroke evaluated at bed side with ultrasound

Conditions: Ischemic Stroke; Carotid Stenosis

Summary: ischemic strokes account for more than 80% of strokes. ischemic strokes are caused by the occlusion of an intracranial artery by a thrombus, responsible for tissue ischemia related to a decrease in local cerebral blood flow (cbs). thus, the management of patients with ischemic strokes is based on the preservation of an area that maintains sufficient intracranial hemodynamics (ih) and achieves the fastest possible recanalization. the impact of the patient's position (supine or seated position) on the ih in the event of narrowing or occlusion of an artery is poorly assessed but may be of particular importance. in practice, variations in blood flow according to the positioning of the patient's body can be measured using a transcranial doppler. it is a simple, non-invasive and painless examination that provides the patient's bed with data on the intracerebral hemodynamic profile of patients. this study was implemented because there are no studies known to us that evaluate the effect of verticalization on intracerebral hemodynamics based on the presence of upstream arterial stenosis or occlusion and other multimodal evaluation data in transcranial doppler.


Eligibility criteria:
inclusion criteria * patient over 18 years of age * acute ischemic stroke or transient ischemic attack * symptoms onset \< 48 hours * absence of homolateral or downstream intracranial stenosis or m1 occlusion * verticalization authorized by the referent clinician. * rankin's score before aic/ait ≤ 2 * non-opposition to participation in the study criteria for inclusion of cases - carotid stenosis of more than 50% nascet or an occlusion criteria for including witnesses - absence of carotid stenosis greater than 50% nascet or occlusion criteria for non-inclusion - disrupted vigilance
paclitaxel and cisplatin as first-line treatment for patients with stage i, stage ii, stage iii, or stage iv ovarian epithelial cancer

Conditions: Ovarian Cancer

Summary: rationale: drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more tumor cells. purpose: this phase ii trial is studying the side effects of giving paclitaxel together with cisplatin as first-line therapy and to see how well it works in treating patients with stage i, stage ii, stage iii, or stage iv ovarian epithelial cancer.

objectives: * to investigate the efficacy and safety of paclitaxel and cisplatin as first-line chemotherapy in patients with stage ic-iv ovarian epithelial cancer. outline: this is a multicenter study. patients receive paclitaxel iv and cisplatin iv once every 2 weeks. treatment repeats every 2 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed epithelial adenocarcinoma of the ovary * stage ic-iv disease * no known or clinical evidence of brain metastasis patient characteristics: * ecog performance status 0-2 * hemoglobin must be ≥ 90 g/l * anc ≥ 2 x 10\^9/l * platelet count ≥ 100 x10\^9/l * serum creatinine ≤ 115 μmol/l * total bilirubin ≤ 25 μmol/l * not pregnant or nursing * no other serious disease which could affect protocol compliance and results * no other prior malignancy within the past 5 years except for curatively treated carcinoma in situ of the cervix or squamous carcinoma of the skin * no peripheral neuropathy ≥ ctcae version 3.0 grade 2 * no known hypersensitivity to any of the study drugs or their excipients * no drug addiction or alcoholism * no disorder which leads to the condition that contraindicates the use of the investigational drugs, or that may affect the patient's compliance with the study requirements prior concurrent therapy: * no prior chemotherapy or radiotherapy for ovarian cancer

Keywords: stage ia ovarian epithelial cancer stage ib ovarian epithelial cancer stage ic ovarian epithelial cancer stage iia ovarian epithelial cancer stage iib ovarian epithelial cancer stage iic ovarian epithelial cancer stage iiia ovarian epithelial cancer stage iiib ovarian epithelial cancer stage iiic ovarian epithelial cancer stage iv ovarian epithelial cancer
fetuin a as a predictor of deterioration of renal function in hypertonic patients

Conditions: Arterial Hypertension

Summary: commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. modified human urine fetuin a (urine fetuin a) with specific modification in urine (fetuin a) can earlier predict the progression of kidney disease in patients with diabetes. studies evaluating urine fetuin a in hypertonic patients are still lacking.

arterial hypertension and diabetes are the most common cause of chronic kidney disease. commonly used parameters for the evaluation of renal function (plasma creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) are sensitive to advanced kidney disease. parameters predicting early kidney impairment are still lacking. modified human urine fetuin a with specific modification in urine (urine fetuin a) presents a new biomarker that seems to be promising in the early prediction of kidney disease in patients with diabetes without microalbuminuria. studies evaluating urine fetuin a in hypertonic patients are still lacking.

Eligibility criteria:
inclusion criteria: * arterial hypertension treated by at least one antihypertensive agent exclusion criteria: * diabetes mellitus of any type, defined as fasting glucose \>7,0 mmol/l or any glycemia \>11,0 mmol/l, or hba1c\>48 mmol/mol * decompensated arterial hypertension defined as office blood pressure \>180/110 mmhg or on ambulatory blood pressure monitoring (abpm) * patient with renal replacement therapy * present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, inflammatory bowel disease, etc.), positivity of antinuclear antibody (ana) / extractable nuclear antigen (ena) screening * acute infection defined as c-reactive protein (crp) \>50 mg/l * severe impairment of liver function defined as cirrhosis, alanine transaminase or aspartate transferase (alt or ast) \>10 µkat/l * terminal incurable illness

Keywords: arterial hypertension resistant arterial hypertension chronic kidney disease fetuin a dnlite ivd103
multimodal imaging of retinal vessels

Conditions: Retinal Blood Vessels; Age-Related Macular Degeneration

Summary: retinal blood flow measurement is of scientific and clinical value. for this purpose retinal vessel morphology (such as diameter, vessel wall thickness, etc) determination is crucial. different imaging modalities might provide divergent results. thus, quantification of such differences is valuable. the present study aims to reveal and quantify differences in vessel morphology between fundus photography, fundus angiography, and optical coherence tomography in health and disease.

this is considered a pilot study and will pe performed on patients scheduled for routine fluorescein angiography. during the study day the following procedures will be performed: * medical history and concomitant medication * blood pressure and heart rate * assessment of visual acuity using snellen vision charts * biomicroscopy * intraocular pressure * funduscopy * iol-master axial length measurement * fundusphotography * optical coherence tomography * fluorescein angiography fundus photography analysis will be performed with an automated software and analysis of both angiography and optical coherence tomography will be performed via the devices inbuilt software.

Eligibility criteria:
inclusion criteria: * written informed consent, clear media exclusion criteria: * any abnormality preventing reliable vessel measurement, pregnancy,
follow up protocol for subjects previously enrolled on nci surgery branch studies

Conditions: Melanoma; Adenocarcinoma; Carcinoma NOS; Neuroendocrine Tumors

Summary: background: the nci surgery branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. objective: this study will allow participants to be followed for up to 15 years following treatment on an nci surgery branch gene therapy trial as required by the fda. eligibility: participants must have been enrolled on an nci surgery branch gene therapy protocol design participants will be followed with a physical examination and blood tests for up to 15 years as required by the fda

background: * patients receiving care at the nih clinical center are required to be enrolled on a clinical protocol. * following participation in a treatment protocol, it may be in the best interest of the patient to continue to be followed at the clinical center. * the national cancer institute surgery branch (nci-sb) conducts clinical trials utilizing gene transfer. the current u.s. food and drug administration (fda) requirements for long-term follow-up are up to fifteen years for some products. as this time-period is frequently longer than studies are expected to be open, a long-term follow-up protocol is necessary to ensure the follow-up of these participants. objective: -primary objective: --provide a mechanism for long-term follow-up of participants who have participated in research studies in the nci-sb. eligibility: * age greater than or equal to 18 years. * participant has been enrolled on an nci-sb treatment protocol. design: * participant will undergo physical exams, laboratory evaluation, imaging, or phone follow-up as clinically indicated. * procedures that entail more than minimal risk to the patient should not be performed for research purposes on this protocol.

Eligibility criteria:
* inclusion criteria: * age greater than or equal to 18 years. * participants who have received treatment on an nci-sb protocol, including gene therapy protocols. (note: participants may be enrolled on this protocol and, at the same time, participate in an active treatment study). * for cohort a:ability of participant or legally authorized representative (lar) to understand and the willingness to sign a written informed consent document. for cohort b: participant is able to provide informed consent. exclusion criteria: -for cohort b: individuals of child-bearing potential (iocbp) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on nci-sb treatment protocols.

Keywords: gene therapy follow-up delayed toxicity natural history adenocarcinoma melanoma neuroendocrine tumors carcinoma
determination of lung maturity and prediction of rds at birth

Conditions: RDS; Premature Birth

Summary: the overall objective is to identify quickly after birth the preterm infants who will develop respiratory distress syndrome (rds) for the purpose of treating them as early as possible with surfactant, to reduce, and if possible, to avoid sequelae, including long-term oxygen treatment. we have therefore developed a quick test, which we believe will be ideal for this type of diagnostics, and will now test the method in a preclinical trial.

in at least 135 preterm infants with gestational age 24-32 weeks we will collect gastric aspirate and hypopharyngeal secretion. the infants are stratified into three groups: gestational age 24-25 weeks, 26-29 weeks and 30-31 weeks. the aspirates will be frozen at -20 centigrade and lecithin-sphingomyelin ratio (l/s) will be analysed retrospectively using fourier transform infrared spectroscopy. the infants will be monitored for the first five days with regard to possible development of rds. clinical and biochemical data will be compared retrospectively. there a no intervention procedures.

Eligibility criteria:
inclusion criteria: * preterm infants with gestational ages of 24 (24+0) to 32 (31+6) weeks. * age \< ½ hour exclusion criteria: * lack of informed consent * lack of aspirate

Keywords: lung maturity rds prematurity lecithin-sphingomyelin ratio spectroscopy chemometrics
art as creative engagement for stroke

Conditions: Stroke

Summary: title: a c e s study: can an arts based creative engagement intervention (cei) following stroke improve psychosocial outcomes? a feasibility trial of a creative engagement intervention for inpatient rehabilitation. this is a feasibility randomised controlled trial of a novel intervention for stroke rehabilitation examining effects of participation in visual arts activities on psychosocial outcomes after stroke. the investigators hypothesise that participation in a visual arts based intervention (cei) will improve stroke recovery variables, mood and self-esteem in stroke survivors receiving in-patient rehabilitation compared to viewing a portfolio of artwork. the results of the study will inform a sample size calculation for a full trial.

summary background: stroke is the main cause of complex adult disability in britain. stroke rehabilitation is typically task orientated, focusing on physical and functional independence. psychosocial consequences of stroke are serious and mediate recovery, influencing family relationships, community reintegration and quality of life. therefore, improving psychosocial outcomes after stroke could improve overall recovery. creative arts programmes are increasingly used to address psychosocial outcomes in long-term and mental health conditions. these programmes focus on positive influences of engagement in creative art activities facilitated by artists. however, there is little research into effects of creative engagement on psychosocial outcomes after stroke. objectives: the purpose of this study is to: conduct a feasibility randomised controlled trial (rct) to test the effects of a participatory visual arts intervention compared to art viewing on psychosocial outcomes following stroke in order to assess effect size for sample size calculation in a full rct. the effects of the cei will be examined in a randomised controlled feasibility trial, which will be run at two stroke rehabilitation units in nhs tayside and will explore the impact of the intervention on a range of psychosocial outcomes. patients meeting inclusion criteria will be randomised to a cei group or an attention control group. the cei group will receive a visual arts intervention of 4-8 sessions during in-patient rehabilitation. the control group will receive an art portfolio to view after randomisation and baseline assessment, with information about community opportunities to engage in art. the groups will be compared on selected psychosocial outcomes. findings will indicate the potential magnitude and direction of change to allow for sample size requirements in development of a subsequent randomised control trial to examine effectiveness of the cei.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke * medically stable and referred for rehabilitation * able to sit upright in chair * 3 or more weeks of rehabilitation planned exclusion criteria: * diagnosis of transient ischemic attack * patinet in acute medical need * patient unable to provide informed consent

Keywords: stroke rehabilitation creative engagement psychosocial art
patient education manual on patients with knee osteoarthritis.

Conditions: Knee Osteoarthritis

Summary: this rct was conducted to see effects of patient education manual on pain, rom and functional performance in patient of knee osteoarthritis. in this study the investigators were provide an educational manual as a home plan in which the investigators educate and guide patients about proper posture, life style modification, precautions and safety measures and home exercise in patient with knee osteoarthritis

this rct was conducted to see effects of patient education manual on pain, rom and functional performance in patient of knee osteoarthritis. in this study the investigators provide an educational manual as a home plan in which they educate and guide patients about proper posture, life style modification, precautions and safety measures and home exercise in patient with knee osteoarthritis. the investigators will divide the patients in two groups. one group was treated with the patient education manual and routine physical therapy and the other group was treated with routine physical therapy alone. after baseline assessment patient was assessed at 2nd, 4th and 6th week and then do final assessment to analyse our results on spss, either patient education manual is helpful in minimising there pain functional limitation and increasing their range of motion. visual analogue scale, goniometry and womec was used to measure outcome regarding pain, range of motion and functional performance in patients with knee osteoarthritis. this study was help full in the management, to improve function and to decrease status of disability in future in patients with knee osteoarthritis.

Eligibility criteria:
inclusion criteria * idiopathic knee oa-i, ii, \&iii exclusion criteria: * post traumatic oa knees * ligament instability * condromalacia patellae * knee replacements * cognitive impairment * rheumatoid arthritis * meniscus injury

Keywords: patient education manual knee o.a pain rom